Wang Q, Yu CR. Association between liver targeted antiviral therapy in colorectal cancer and survival benefits: An appraisal. World J Clin Cases 2020; 8(11): 2111-2115 [PMID: 32548140 DOI: 10.12998/wjcc.v8.i11.2111]
Corresponding Author of This Article
Chao-Ran Yu, MD, PhD, Surgeon, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, 270 Dongan Road, Shanghai 200025, China. chaoran_yu@yeah.net
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 6, 2020; 8(11): 2111-2115 Published online Jun 6, 2020. doi: 10.12998/wjcc.v8.i11.2111
Association between liver targeted antiviral therapy in colorectal cancer and survival benefits: An appraisal
Qiang Wang, Chao-Ran Yu
Qiang Wang, Chao-Ran Yu, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Shanghai 200025, China
Author contributions: Wang Q and Yu CR designed the research; Wang Q prepared the literature review and wrote the paper; Yu CR coordinated the reference review and performed the majority of the writing.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors who contributed their efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Chao-Ran Yu, MD, PhD, Surgeon, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, 270 Dongan Road, Shanghai 200025, China. chaoran_yu@yeah.net
Received: March 7, 2020 Peer-review started: March 7, 2020 First decision: March 24, 2020 Revised: April 10, 2020 Accepted: May 1, 2020 Article in press: May 1, 2020 Published online: June 6, 2020 Processing time: 93 Days and 3.1 Hours
Abstract
In colorectal cancer (CRC), liver metastasis remains a major contributor to the cause of cancer-related death. Putative biomarkers, therapeutic efficacy, and drug insensitivity still pose clinical challenges for metastatic CRC patients. Interestingly, previous studies indicated that tumor cells in CRC did not metastasize to the injured liver, which included hepatitis or cirrhotic liver. The benefits of antiviral therapy on hepatocellular carcinoma have also been identified. This review discusses the role of antiviral therapy on the liver. Antiviral therapy may reduce potential liver metastasis associated with CRC in several mechanistic aspects.
Core tip: Liver metastasis is one of the major contributors to the cancer-related deaths in colorectal cancer. Previous studies reported that tumor cells rarely metastasize to the injured liver during the disease course. Others also identified survival benefits brought by antiviral therapy upon hepatocellular carcinoma. Hereby, this review discusses the potential impact of antiviral therapy in reducing liver metastasis of colorectal cancer.
